Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Paradigm Reports Phase 3 Trial Futility as Administrators Review Next Steps

PAR: $0.245 +0.00% · MC: $153M

Paradigm Biopharmaceuticals reported that its Phase 3 trial met the pre-set futility criterion, and voluntary administrators were appointed at quarter-end. Since then, a regional analysis identified encouraging pain and function findings, while independent review of the data is underway to inform assessment of the program and possible future development. The company ended the quarter with approximately A$4 million in cash; a recent court-approved extension gives administrators until January to convene a creditors’ meeting, though they anticipate acting sooner.

Source announcements: 2026-10-30 11:12 to 2026-10-30 11:12 Sydney time
Story updated 2026-10-30 11:14 Sydney time
SourcesSeptember 2026 Quarterly Activities Report & Appendix 4C
Comments